153 related articles for article (PubMed ID: 10753224)
1. Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumor induction with N-methyl-N-nitrosourea.
Qin X; Shibata D; Gerson SL
Carcinogenesis; 2000 Apr; 21(4):833-8. PubMed ID: 10753224
[TBL] [Abstract][Full Text] [Related]
2. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.
Qin X; Zhou H; Liu L; Gerson SL
Carcinogenesis; 1999 Sep; 20(9):1667-73. PubMed ID: 10469609
[TBL] [Abstract][Full Text] [Related]
3. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT.
Qin X; Liu L; Gerson SL
Oncogene; 1999 Jul; 18(30):4394-400. PubMed ID: 10439048
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability detected in tumor-related genes in C57BL/6J mice with thymic lymphoma induced by N-methyl-N-nitrosourea.
Zhang S; Huo X; Li Z; Li X; Tang W; Li C; Guo M; Du X; Chen Z
Mutat Res; 2015 Dec; 782():7-16. PubMed ID: 26498208
[TBL] [Abstract][Full Text] [Related]
5. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice.
Yao X; Buermeyer AB; Narayanan L; Tran D; Baker SM; Prolla TA; Glazer PM; Liskay RM; Arnheim N
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6850-5. PubMed ID: 10359802
[TBL] [Abstract][Full Text] [Related]
6. Elevated mutant frequencies and increased C : G-->T : A transitions in Mlh1-/- versus Pms2-/- murine small intestinal epithelial cells.
Baross-Francis A; Makhani N; Liskay RM; Jirik FR
Oncogene; 2001 Feb; 20(5):619-25. PubMed ID: 11313994
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice.
Baker SM; Harris AC; Tsao JL; Flath TJ; Bronner CE; Gordon M; Shibata D; Liskay RM
Cancer Res; 1998 Mar; 58(6):1087-9. PubMed ID: 9515784
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance.
Gibson SL; Narayanan L; Hegan DC; Buermeyer AB; Liskay RM; Glazer PM
Cancer Lett; 2006 Dec; 244(2):195-202. PubMed ID: 16426742
[TBL] [Abstract][Full Text] [Related]
9. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair.
Prolla TA; Baker SM; Harris AC; Tsao JL; Yao X; Bronner CE; Zheng B; Gordon M; Reneker J; Arnheim N; Shibata D; Bradley A; Liskay RM
Nat Genet; 1998 Mar; 18(3):276-9. PubMed ID: 9500552
[TBL] [Abstract][Full Text] [Related]
10. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice.
Kawate H; Itoh R; Sakumi K; Nakabeppu Y; Tsuzuki T; Ide F; Ishikawa T; Noda T; Nawata H; Sekiguchi M
Carcinogenesis; 2000 Feb; 21(2):301-5. PubMed ID: 10657972
[TBL] [Abstract][Full Text] [Related]
11. Pms2 is a genetic enhancer of trinucleotide CAG.CTG repeat somatic mosaicism: implications for the mechanism of triplet repeat expansion.
Gomes-Pereira M; Fortune MT; Ingram L; McAbney JP; Monckton DG
Hum Mol Genet; 2004 Aug; 13(16):1815-25. PubMed ID: 15198993
[TBL] [Abstract][Full Text] [Related]
12. Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice.
Xu XS; Narayanan L; Dunklee B; Liskay RM; Glazer PM
Cancer Res; 2001 May; 61(9):3775-80. PubMed ID: 11325851
[TBL] [Abstract][Full Text] [Related]
13. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts.
Fiumicino S; Martinelli S; Colussi C; Aquilina G; Leonetti C; Crescenzi M; Bignami M
Int J Cancer; 2000 Feb; 85(4):590-6. PubMed ID: 10699935
[TBL] [Abstract][Full Text] [Related]
15. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
[TBL] [Abstract][Full Text] [Related]
16. Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells.
Shin CY; Mellon I; Turker MS
Oncogene; 2002 Mar; 21(11):1768-76. PubMed ID: 11896608
[TBL] [Abstract][Full Text] [Related]
17. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: case series, review and follow-up guidelines.
Herkert JC; Niessen RC; Olderode-Berends MJ; Veenstra-Knol HE; Vos YJ; van der Klift HM; Scheenstra R; Tops CM; Karrenbeld A; Peters FT; Hofstra RM; Kleibeuker JH; Sijmons RH
Eur J Cancer; 2011 May; 47(7):965-82. PubMed ID: 21376568
[TBL] [Abstract][Full Text] [Related]
18. Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres.
Siegl-Cachedenier I; Muñoz P; Flores JM; Klatt P; Blasco MA
Genes Dev; 2007 Sep; 21(17):2234-47. PubMed ID: 17785530
[TBL] [Abstract][Full Text] [Related]
19. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
20. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
